Reuters logo
BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy
2017年6月5日 / 中午11点32分 / 5 个月前

BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy

June 5 (Reuters) - Merck & Co Inc-

* New data from phase 2 i-spy 2 trial shows improved outcomes with combination of Merck’S Keytruda® (pembrolizumab) plus standard neoadjuvant therapy in patients with high-risk breast cancer

* Merck - findings showed addition of keytruda increased estimated pathologic complete response rate nearly threefold in patients with tnbc (60% versus 20%)

* Merck & Co Inc - ‍keytruda has graduated from i-spy 2 trial for all signatures in which it was tested (tnbc, all her2-, and hr+/her2-)​

* Merck & Co Inc says in keynote-006, keytruda was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma

* Merck - findings showed addition of keytruda increased estimated pathologic complete response rate in patients with hr+/her2- breast cancer (34% versus 13%)

* Merck & Co Inc - in keytruda arm of trial, five of six patients presented with adrenal insufficiency after completion of ac

* Merck & Co Inc - in keytruda arm of trial, one patient presented with adrenal insufficiency during keytruda treatment Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below